Mantar Zehirlenmeleri

Authors

Sinan Yıldırım

Synopsis

Mantar zehirlenmeleri, özellikle bahar aylarında doğada yetişen yabani mantarların tüketilmesi sonucu gelişen ve yüksek yatış ile mortalite oranına sahip önemli bir sağlık sorunudur. Dünya genelinde zehirlenmelerin ve ölümlerin yaklaşık %95’inden amatoksin içeren Amanita türleri, özellikle de Amanita phalloides sorumludur. Mantarlar içerdikleri toksin türlerine göre siklopeptid, koprin, muskarin, giromitrin, psilosibin, orellanin, ibotenik asit/muskimol ve involutin olmak üzere sekiz grupta sınıflandırılır. Bu toksinler gastrointestinal, kardiyovasküler, renal ve santral sinir sistemini farklı mekanizmalarla etkiler. Siklopeptid grubundaki amatoksinler, RNA polimeraz II’yi inhibe ederek protein sentezini bozar ve gastrointestinal semptomlardan başlayarak akut karaciğer ile böbrek yetmezliğine ilerleyen dört fazlı bir klinik tablo oluşturur. Zehirlenmeler semptom başlama süresine göre erken (ilk 6 saat), geç (6-24 saat) ve gecikmiş (24 saatten sonra) olarak ayrılır. Tanıda en kritik adım detaylı bir anamnez olup idrarda ELISA yöntemiyle amanitin tespiti yüksek duyarlılığa sahiptir. Tedavi sürecinde hava yolu desteği ve sıvı resüsitasyonunun yanı sıra enterohepatik sirkülasyonu kesmek için tekrarlayan aktif kömür uygulaması büyük önem taşır. Hepatoprotektif amaçla yüksek doz Penisilin G, intravenöz silibinin ve N-asetilsistein kullanılırken, hemodiyaliz yalnızca akut böbrek yetmezliği endikasyonunda tercih edilir. Korunmanın temel kuralı ise doğadan toplanan yabani mantarları kesinlikle tüketmeyip yalnızca kültür mantarlarını tercih etmektir.

Mushroom poisonings are a significant public health issue with high hospitalization and mortality rates, arising primarily from the consumption of wild mushrooms growing in nature, especially during the spring months. Worldwide, Amanita species containing amatoxin, particularly Amanita phalloides, are responsible for approximately 95% of poisonings and fatalities. Mushrooms are classified into eight groups based on the types of toxins they contain: cyclopeptide, coprine, muscarine, gyromitrin, psilocybin, orellanine, ibotenic acid/muscimol, and involutin. These toxins affect the gastrointestinal, cardiovascular, renal, and central nervous systems through various mechanisms. Cyclopeptide-group amatoxins inhibit RNA polymerase II, disrupting protein synthesis and causing a four-phase clinical presentation that progresses from gastrointestinal symptoms to acute liver and kidney failure. Poisonings are categorized based on symptom onset duration as early-onset (first 6 hours), late-onset (6–24 hours), and delayed-onset (after 24 hours). The most critical diagnostic step is taking a detailed patient history, and detecting amanitin in urine using the ELISA method has high sensitivity. In the treatment process, alongside airway support and fluid resuscitation, repeating doses of activated charcoal are of vital importance to interrupt enterohepatic circulation. High-dose Penicillin G, intravenous silybin, and N-acetylcysteine are used for hepatoprotective purposes, whereas hemodialysis is preferred strictly for acute kidney failure indications. The fundamental rule of prevention is to strictly avoid consuming wild mushrooms collected from nature and choose only cultivated mushrooms.

References

Lee E. Extraordinary mushrooming. The San Diego Tribune, April 9, 1997.

Berger KJ, Guss DA. Mycotoxins revisited: Part I. J Emerg Med. 2005; 28: 53–62.

Brent J, Kulig K. Mushrooms. In: Haddad LM, Shannon MW, Winchester JF, eds. Clinical management of poisoning and drug overdosez, 3rd edn. Philadelphia: WB Saunders Company; 1998: 364–365.

Watson WA, Litovitz TL, Rodgers GC, et al. 2002 annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am J Emerg Med 2003; 21: 353–421.

Goldfrank LR. Mushrooms. In: Nelson LS, Lewin NA, Howland MA, Hoffman RS, Goldfrank LR, Flomenbaum NE. Goldfrank’s Toxicologic Emergencies. 9th. New York: McGraw-Hill; 2011:1522-36.

Schneider SM, Vanscoy G, Michelson EA: Failure of cimetidine to affect phalloidin toxicity. Vet Hum Toxicol 1991; 33: 17–18.

Vetter J. Toxins of Amanita phalloides. Toxicon 1998; 36: 13–24.

Berger KJ, Guss DA. Mycotoxins revisited: Part II. J Emerg Med. 2005; 28:175–83.

Leathem AM, Dorran TJ. Poisoning due to raw Gyromitra esculenta (false morels) west of the Rockies. CJEM. 2007; 9: 127–30.

Borowiak KS, Ciechanowski K, Walosczyk P. Psilocybin mushroom (Psilocybe semilanceata) intoxication with myocardial infarction. J Toxicol Clin Toxicol 1998; 36: 47–49.

Franz M, Regele H, Kirchmair M, et al: Magic mushrooms: Hope for a “cheap high” resulting in end-stage renal failure. Nephrol Dial Transplant 1996; 11: 2324–2327.

Magdalane J, Ostrowska A, Podhorska Okalow M, et al. Early morphological and functional alterations in canine hepatocytes due to alpha-amanitin, a major toxin of Amanita phalloides. Arch Toxicol 2009;83:55–60.

A. Himmelmann, G. Mang, and S. Schnorf-Huber, Lethal ingestion of stored Amanita phalloides mushrooms. Swiss Medical Weekly, vol. 131, no. 41-42, pp. 616–617, 2001.

Letschert K, Faulstich H, Keller D, at al. Molecular characterization and inhibition of amanitin uptake into human hepatocytes. Toxicol Sci. 2006 May;91(1):140-9.

C. Busi, L. Fiume, and D. Costantino. Amanitatoxins in gastroduodenal fluid of patients poisoned by the mushroom, Amanita phalloides. New England Journal of Medicine, vol. 300, no. 14, p. 800, 1979.

R. B. Gibbons. Mushroom poisoning. Comprehensive therapy, vol. 8, no. 12, pp. 33–39, 1982.

L. Fiume, S. Sperti, L. Montanaro, C at al. Amanitins do not bind to serum albumin. The Lancet, vol. 1, no. 8021, p. 1111, 1977.

H. Faulstich, A. Talas, and H. H. Wellhoner. Toxicokinetics of labeled amatoxins in the dog. Archives of Toxicology, vol. 56, no. 3, pp. 190–194, 1984.

Parant F, Peltier L, Lardet G, et al. Phalloidin syndrome: role of elisa based assay for the detection of alpha- and gamma amanitins in urine, preliminary results. Acta Clin. Belg. Suppl 2006; :11.

Jaeger A, Jehl F, Flesch F, et al. Kinetics of amatoxins in human poisoning: therapeutic implications. J Toxicol Clin Toxicol 1993;31:63.

J. Ward, K. Kapadia, E. Brush, and S.D. Salhanick, Amatoxın poısonıng: case reports and revıew of current therapies. The Journal of Emergency Medicine, Vol. 44, No. 1, pp. 116–121, 2013.

Enjalbert F, Rapior S, Nouguier-Soulé J at al. Treatment of amatoxin poisoning: 20-year retrospective analysis. J Toxicol Clin Toxicol. 2002;40(6):715-57.

National Center for Complementary and Alternative Medicine. Milk thistle. Available at: http://nccam.nih.gov/health/milkthistle/ataglance. htm. Accessed February 14,2011.

Faulstich H, Zilker TR. Amatoxins. In: Spoarke DG, Rumack BH, eds. Handbook of Mushroom Poisoning. Diagnosis and Treatment. Boca Raton. FL:CRCpress; 1994. p.233-49.

Mitchell, ST. New Comprehensive Amatoxin Mushroom Poisoning (AMP) Treatment Protocol. ClinTox 2010; 48:628.

Bergis D, Friedrich-Rust M, Zeuzem S, Betz C, Sarrazin C, Bojunga J. Treatment of Amanita phalloides intoxication by fractionated plasma separation and adsorption (Prometheus®). J GastrointestinLiverDis. Jun 2012;21(2):171-6.

Salhanick SD, Wax PM, Schneider SM. Inresponse to Tong TC, et al. Comparative treatment of alpha-amanitin poisoning with N-acetylcysteine, benzylpenicillin, cimetidine, thiocticacid, and silybinin a murine model. AnnEmergMed 2008;52:184–5; authorreply 185.

Mullins ME, HorowitzBZ. The futility of hemoperfusion and hemodialysis in Amanita phalloides poisoning. Vet Hum Toxicol. 2000 Apr;42(2):90-1.

Wittebole X, Hantson P. Use of the molecular adsorbent recirculating system (MARS™) for the management of acute poisoning with or without liver failure. Clin. Toxicol (Phila). Nov 2011;49(9):782-93.

Downloads

Published

April 6, 2021

License

License